Protein C News and Research

RSS

caprotec bioanalytics launches three new caproKits based on its CCMS technology

caprotec bioanalytics announced today the commercial launch of three new caproKits(TM), enabling the discovery, identification and characterization of proteins belonging to the groups of metallo-proteases, histon-deacetylases and GDP/GTP binding proteins.

27 Jan 2010

Obese children face increased risk of stroke and heart disease

By as early as 7 years of age, being obese may raise a child's risk of future heart disease and stroke, even in the absence of other cardiovascular risk factors such as high blood pressure, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

27 Jan 2010

Antibiotics may be effective in fighting MRSA infections

Researchers at the University of Illinois at Chicago and Israel's Weizman Institute of Science have found that two antibiotics working together might be more effective in fighting pathogenic bacteria than either drug on its own.

27 Jan 2010

Ecolab and AvidBiotics to develop new technology to reduce E. coli in red meat products

Ecolab Inc. has entered into an agreement with AvidBiotics Corp. under which they will jointly work to develop a new technology that could significantly reduce the presence of the pathogen E. coli O157:H7 in red meat products.

27 Jan 2010

Universite de Montreal researchers are developing leptin-based pill to control hunger

A Universit- de Montr-al research team is developing a pill composed of leptin, the protein that tells our brain to stop eating. "Mice deprived of leptin will not stop eating. They become so big they have trouble moving around," says Mo-se Bendayan, a pathology professor at the Universit- de Montr-al Faculty of Medicine who has studied the leptin protein extensively.

27 Jan 2010

Texas to invest $4.5 mn in cancer research at UT Health Science Center

Texas plans to invest $3 billion in cancer research over the next 10 years and six scientists at The University of Texas Health Science Center at Houston are among the first to receive grants.The researchers, whose grants total $4.5 million, are working to protect girls from cervical cancer, to interrupt tumor growth at the molecular level and to develop a new approach for the treatment of colon cancer, among other cutting-edge projects.

27 Jan 2010

Promising results in mice could prevent fatal iron buildup in humans

A new study shows that a protein found in blood alleviates anemia, a condition in which the body's tissues don't get enough oxygen from the blood. In this animal study, injections of the protein, known as transferrin, also protected against potentially fatal iron overload in mice with thalassemia, a type of inherited anemia that affects millions of people worldwide.

27 Jan 2010

Curemark commences CM-AT Phase III autism clinical trial enrollment at ten sites

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that the company is now enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at ten sites across the country.

27 Jan 2010

NPD Group names yogurt as food trend of the decade

Americans are eating more yogurt than ever before, and Dairy Council of California advises that consumers can benefit from even more culture.

25 Jan 2010

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.

25 Jan 2010

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies’ long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

25 Jan 2010

Researchers identify new gene signature that predicts cancer recurrence in certain breast tumors

Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.

24 Jan 2010

Loss of key proteins may account for molecular abnormalities associated with myotonic dystrophy

Research on the genetic defect that causes myotonic muscular dystrophy has revealed that the mutation disrupts an array of metabolic pathways in muscle cells through its effects on two key proteins.

24 Jan 2010

New technology may allow scientists to monitor real time activity of protein network

A new assay capable of examining hundreds of proteins at once and enabling new experiments that could dramatically change our understanding of cancer and other diseases has been invented by a team of University of Chicago scientists.

24 Jan 2010

Healthy eating trend fuels probiotic yogurt sales

Call it “the sweet spot.” The Greek Gods Yogurt is in the enviable target zones where yogurt sales are domestically growing most. In its most recent Nov. 2009 report, Mintel’s industry data found the probiotic and protein-packed Greek Gods Yogurt brand situated in yogurt’s most evident growth segments.

23 Jan 2010

U.S. blood banks have sufficient blood to meet the needs of Haiti victims

The AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism has determined that the current blood supply in the United States is adequate to fill any requests received to support the present needs of Haitian hospitals, though ongoing infrastructure and transportation issues in Haiti could delay receipt of those supplies to patients.

23 Jan 2010

Study of 16INK4A gene's role in progression of retinoblastoma

Retinoblastoma is a pediatric eye cancer initiated by the loss or mutation of both copies of the retinoblastoma gene. Current evidence suggests that additional genetic alterations are required for retinoblastoma to become fully malignant.

23 Jan 2010

Study: Warburg effect promotes rapid cell proliferation and tumor growth

A team of scientists led by Professor Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory has discovered molecular factors in cancer cells that boost the production of an enzyme that helps alter the cells' glucose metabolism. The altered metabolic state, called the Warburg effect, promotes extremely rapid cell proliferation and tumor growth. Adrian Krainer, Ph.D.

23 Jan 2010

A personal account of a heart attack survivor

People would say, myself included, that this can not be true. I had lived my life being active and fit. I had been living a healthful and happy life, trying to set a good example for those around me.

23 Jan 2010

USPTO issues new patent for Advaxis' intellectual property portfolio

The U.S. Patent and Trademark Office (USPTO) issued today patent 7,635,479, "Compositions and Methods for Enhancing the Immunogenicity of Antigens,” by Dr. Yvonne Paterson, et al, which is assigned to the Trustees of the University of Pennsylvania and licensed to Advaxis, Incorporated (OTCBB: ADXS).

22 Jan 2010